Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-11-29
2010-02-23
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S430000, C514S183000, C514S559000, C514S560000, C548S968000, C549S090000, C549S561000
Reexamination Certificate
active
07666905
ABSTRACT:
Methods and pharmaceutical compositions comprise at least one hepoxilin analog of the formula (I)wherein X and R3are as defined herein. The methods are directed to treatment of a cancer and for promotion of a apoptosis in a cancer cell.
REFERENCES:
patent: 5616607 (1997-04-01), Pace-Asciak et al.
patent: 6093741 (2000-07-01), Gosselin et al.
patent: 6391305 (2002-05-01), Feng et al.
patent: WO9729751 (1997-08-01), None
patent: WO9959578 (1999-11-01), None
patent: WO0110422 (2001-02-01), None
patent: WO0238157 (2002-05-01), None
Pace-Asciak et. al. Current Pharmaceutical Design, 2006, 12, 963-969.
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56.
Sawyers et. al. J. Clin. Onco. 19(18), 2001, 13s-16s.
Merck Manual of Diagnostics,17th Edition, 1999, pp. 973-995.
Arndt et al., “Liposomal Bleomycin: Increased Therapeutic Activity and Decreased Pulmonary Toxicity in Mice” Drug Delivery (2001) vol. 8, pp. 1-7.
Mauro et al, (2002), “STI571: A Paradigm of New Agents for Cancer Therapeutics”,J. Clin. Oncol., V. 20, pp. 325-334.
Seppa, N., (2001), “Leukemia Overpowers Drug in Two Ways”,Science N ews, V. 159, p. 389.
Rajaratnam et al, (2001), “Imatinib for Chronic Myelogenous Leukemia: A Nice Mess”,Lancet, V. 358, p. 1902.
O'Brian, S.G., (2001), “Imatinib for Chronic Myelogenous Leukemia: A Nice Mess”,Lancet, pp. 1902-1903.
Lim et al, (2001), “Imatinib for Chronic Myelogenous Leukemia: A Nice Mess”,Lancet, V. 358, p. 1903.
Cheng, G.S., (2000), “Dramatic Results in Trial of New Leukemia Drug”,Family Practice News, Feb. 1, 2000, v. 10, p. 1.
Jankov et al, (2002), “Hepoxilin Analogs Inhibit Bleomycin-Induced Pulmonary Fibrosis in the Mouse”J.P.E.T., V. 301, pp. 435-440.
Weisberg et al (2000), “Mechanism of Resistance to the ABL Tyrosine Kinase Inhibitor ST1571 in BCR/ABL-transformed hematopoietic cell lines”,Blood, V. 95, pp. 3498-3505.
Dinsmore & Shohl LLP
Jiang Shaojia Anna
Olson Eric S
LandOfFree
Compositions comprising hepoxilin analogs and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions comprising hepoxilin analogs and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions comprising hepoxilin analogs and their use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201518